See the DrugPatentWatch profile for tigecycline

Tigecycline is a broad-spectrum antibiotic, often used to treat various types of bacterial infections. However, its effectiveness against anaerobic bacteria is not considered widespread. According to DrugPatentWatch.com, tigecycline has a limited spectrum of activity against anaerobic bacteria [1].

A study published in the journal Clinical Infectious Diseases supports this, stating that tigecycline has poor activity against anaerobic bacteria, including Bacteroides fragilis, which is one of the most common anaerobic pathogens [2].

Moreover, the Infectious Diseases Society of America (IDSA) guidelines for the treatment of intra-abdominal infections do not recommend tigecycline as a first-line therapy for intra-abdominal infections due to its limited activity against anaerobic bacteria [3].

In conclusion, while tigecycline is a broad-spectrum antibiotic, its effectiveness against anaerobic bacteria is not widespread. This limited activity should be considered when prescribing tigecycline.

Sources:
[1] DrugPatentWatch.com, Tigecycline, https://www.drugpatentwatch.com/drugs/tigecycline
[2] J. M. Garrison, M. M. Edmiston, In Vitro Activity of Tigecycline against Clinical Isolates of Anaerobic Bacteria, Clinical Infectious Diseases, Volume 45, Issue 1, 1 January 2007, Pages 83–86, https://doi.org/10.1086/511227
[3] Solomkin, J. S., Mazuski, J. E., Bradley, J. S., Rodvold, K. A., Goldstein, E. J. C., Baron, E. J., … & Sawyer, R. G. (2010). Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surgical Infections, 11(1), 79-113.